Achillion Pharmaceuticals gives HCV pipeline update, shares collapse


Achillion Pharmaceuticals (ACHN) gives an HCV pipeline update.

Sovaprevir is still on clinical hold even though the company says it has "addressed all issues noted in the FDA's June 29, 2013 letter." (previous)

As for the sovaprevir/ACH-3102/ribavirin combo, rapid virologic response was 79%. That doesn't appear to stack up too well with results from BMY, GILD, and ABBV if one assumes RVR is a good indicator of SVR. (more on this here)

Additionally, the company indicates it will advance ACH-2684 into Phase 2 combo studies. (PR)

ACHN -44% AH

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs